Thus, blocking the different immune checkpoints has become a cornerstone of modern immunotherapy and the usefulness of CTLA-4, PD-1 and PD-L1/2 blockers in advanced melanoma therapy has been most widely studied to date (29, 30). The gene discussed is CTLA4; the disease is melanoma.